Publications
The HDAC6 inhibitor AVS100 induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy
Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma
The HDAC6-specific inhibitor AVS100 blocks M2 polarization of tumor associated macrophages and potentiates immunotherapy in preclinical tumor models
Discovery of a New Isoxazole-3-hydroxamate Based Histone Deacetylase 6 Inhibitor SS-208 (AVS100) with Antitumor Activity in Syngeneic Melanoma Mouse Models
Inhibition of HDAC6 and HDAC11 Has an Opposite Effect on Inflammation and the Functional Phenotype of Macrophages in the Tumor Microenvironment
Reprogramming Macrophages with HDAC6 Inhibitors for Anti-cancer Macrophage-based Cell Therapy
Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma
The HDAC6-specific inhibitor AVS100 blocks M2 polarization of tumor associated macrophages and potentiates immunotherapy in preclinical tumor models
Discovery of a New Isoxazole-3-hydroxamate Based Histone Deacetylase 6 Inhibitor SS-208 (AVS100) with Antitumor Activity in Syngeneic Melanoma Mouse Models
Inhibition of HDAC6 and HDAC11 Has an Opposite Effect on Inflammation and the Functional Phenotype of Macrophages in the Tumor Microenvironment
Reprogramming Macrophages with HDAC6 Inhibitors for Anti-cancer Macrophage-based Cell Therapy
